Clinical Trials on Cystic Fibrosis - Complete

Total 9187 results

Assistance Publique - Hôpitaux de Paris
Societe Francaise de la Mucoviscidose; Effi-Stat

Completed

Real-life Follow-up of Cystic Fibrosis Patients Treated With Ivacaftor+Lumacaftor (Orkambi*) (ORKAMBI)

Cystic Fibrosis

France
Royal Brompton & Harefield NHS Foundation Trust
National Institute for Health Research, United Kingdom

Completed

Improving Outcome Measures For Adult CF ACT Trials

Cystic Fibrosis

United Kingdom
Vertex Pharmaceuticals Incorporated

Completed

Evaluation of VX 445/TEZ/IVA in Cystic Fibrosis Subjects 6 Through 11 Years of Age

Cystic Fibrosis

United States, Canada, Australia, Ireland, United Kingdom
Santhera Pharmaceuticals

Completed

Clinical Study to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of POL6014 in Patients With CF

Cystic Fibrosis

Germany
University Hospital, Lille

Terminated

Evaluation of Short Antibiotic Combination Courses Followed by Aerosols in Cystic Fibrosis (TOBRAMUC)

Cystic Fibrosis

France
Parion Sciences
Vertex Pharmaceuticals Incorporated

Completed

A Study to Evaluate the Safety and Efficacy of VX-371 in Subjects With Cystic Fibrosis Who Are Homozygous for the F508del-CFTR Mutation

Cystic Fibrosis

United Kingdom, United States, France, Ireland
Hospices Civils de Lyon

Completed

Cystic Fibrosis Adherence Study (KINOBS)

Cystic Fibrosis

France
Parion Sciences
Vertex Pharmaceuticals Incorporated

Completed

Clearing Lungs With Epithelial Sodium Channel (ENaC) Inhibition in Cystic Fibrosis (CF) (CLEAN-CF)

Cystic Fibrosis

United States
Boston Children's Hospital

Completed

Clinical Utility of the 1-minute Sit to Stand Test as a Measure of Submaximal Exercise Tolerance in Patients With Cystic Fibrosis During Acute Pulmonary Exacerbation

Cystic Fibrosis

United States
Vertex Pharmaceuticals Incorporated

Completed

A Phase 3 Study of VX-445 Combination Therapy in Cystic Fibrosis (CF) Subjects Heterozygous for F508del and a Gating or Residual Function Mutation (F/G and F/RF Genotypes)

Cystic Fibrosis

United States, Spain, Ireland, Belgium, Netherlands, United Kingdom, Australia, France, Canada, Denmark, Germany, Italy, Israel
Steven M Rowe

Completed

G551D Observational Study- Expanded to Additional Genotypes and Extended for Long Therm Follow up (GOAL-e2) (GOAL- e2)

Cystic Fibrosis

United States
Boehringer Ingelheim

Terminated

A 4-week Study to Test Different Doses of BI 1265162 in Adolescents and Adults With Cystic Fibrosis Using the Respimat® Inhaler - BALANCE - CF™1

Cystic Fibrosis

United States, Spain, Belgium, Germany, Canada, United Kingdom, Sweden, France
Rush University Medical Center

Completed

Efficacy of TOBI Podhaler vs. Tobramycin Inhalation Solution (PETIS)

Cystic Fibrosis

United States
NovaBiotics Ltd.
Agility Clinical, Inc.; PSR Group B.V.

Completed

A Study of the Dosing, Efficacy, and Safety of Oral Cysteamine in Adult Patients With Cystic Fibrosis Exacerbations (CARE-CF1)

Cystic Fibrosis

United States, United Kingdom, Italy
Sheffield Teaching Hospitals NHS Foundation Trust

Completed

Evaluation of a Behavioural Intervention Using App Technology in CF (EAT-CF)

Cystic Fibrosis

United Kingdom
University of Colorado, Denver
Cystic Fibrosis Foundation; Colorado Clinical & Translational Sciences Institute

Completed

Improving Treatment of Nontuberculous Mycobacterial Infection in Cystic Fibrosis

Cystic Fibrosis

United States
Carmel Medical Center

Completed

Real Life Evaluation of the Multi-organ Effects of Lumacaftor/Ivacaftor on F508del Homozygous Cystic Fibrosis Patients.

Cystic Fibrosis
Novartis Pharmaceuticals

Completed

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of QAU145 in Patients With Cystic Fibrosis

Cystic Fibrosis

United States
Liminal BioSciences Ltd.

Terminated

Study of Safety, Tolerability & Efficacy in Cystic Fibrosis Patients With Abnormal Glucose Tolerance

Cystic Fibrosis

Canada
University of Miami
University of Alabama at Birmingham; University of Kansas Medical Center; Children... and other collaborators

Terminated

Losartan and Inflammation in Cystic Fibrosis

Cystic Fibrosis

United States
Pharmaxis
ethica Clinical Research Inc.; Europe: KasaConsult bvba, Hoegaarden, Belgium; Argentina: Resolution Latin America; Buenos Aires, Argentina

Completed

Long Term Administration of Inhaled Mannitol in Cystic Fibrosis

Cystic Fibrosis

United States, France, Belgium, Canada, Argentina, Germany, Netherlands
MemorialCare Health System
University of California, Irvine

Completed

Impact of Telerehabilitation Training on Pediatric Cystic Fibrosis Patients: An Exploratory Study

Cystic Fibrosis

United States
Hannover Medical School
Heidelberg University; University of Giessen

Completed

ICM to Evaluate the Activation of p.Phe508del-CFTR by Lumacaftor in Combination With Ivacaftor (OrkambiFacts)

Cystic Fibrosis

Germany
Insmed Incorporated

Completed

Multidose Safety and Tolerability Study of Dose Escalation of Liposomal Amikacin for Inhalation (ARIKACE™)

Cystic Fibrosis

Poland, Ukraine, Serbia, Belgium, Hungary, Slovakia, North Macedonia
AO GENERIUM

Completed

Efficacy and Safety of Tigerase® vs. Pulmozyme® in Patients With Cystic Fibrosis

Fibrosis | Cystic Fibrosis

Russian Federation
University Hospital, Bordeaux

Unknown

Polyethylene Glycol and Intestinal Inflammation in Cystic Fibrosis (MUCOLAX)

Cystic Fibrosis
Koronis Biomedical Technologies
Johns Hopkins University

Unknown

Cystic Fibrosis Remote Monitoring System

Cystic Fibrosis
University of Alabama at Birmingham
Cystic Fibrosis Foundation

Completed

A Two-Part Multicenter Prospective Longitudinal Study of CFTR-dependent Disease Profiling in Cystic Fibrosis (PROSPECT) (PROSPECT)

Cystic Fibrosis

United States
Vertex Pharmaceuticals Incorporated

Completed

A Phase 3 Study of VX-445 Combination Therapy in Subjects With Cystic Fibrosis Heterozygous for the F508del Mutation and a Minimal Function Mutation (F/MF)

Cystic Fibrosis

United States, Belgium, Netherlands, United Kingdom, Canada, Germany, Australia, France, Italy, Czechia, Austria, Greece, Sweden
PTC Therapeutics
Cystic Fibrosis Foundation; ECFS-Clinical Trial Network (ECFS-CTN)

Completed

Study of Ataluren in Nonsense Mutation Cystic Fibrosis (ACT CF)

Cystic Fibrosis

United States, Spain, United Kingdom, Netherlands, Germany, France, Belgium, Italy, Australia, Argentina, Brazil, Bulgaria, Canada, Greece, Israel, Poland
Proteostasis Therapeutics, Inc.

Completed

Safety, Tolerability, and Pharmacokinetics of PTI-808, PTI-801, and PTI-428 Combination Therapy in Subjects With Cystic Fibrosis

Cystic Fibrosis

United Kingdom
Proteostasis Therapeutics, Inc.

Completed

Study Assessing PTI-428 Safety, Tolerability, and Pharmacokinetics in Subjects With Cystic Fibrosis on KALYDECO® as Background Therapy

Cystic Fibrosis

United Kingdom
King's College Hospital NHS Trust
King's College London

Completed

LBM & Lung Function in Adolescents With CF

Cystic Fibrosis

United Kingdom
Queen Mary University of London

Completed

Air Pollution and Children With Cystic Fibrosis

Cystic Fibrosis

United Kingdom
University Hospital, Montpellier

Completed

Educational Program Through Video Conference for Inhaled Therapies in Cystic Fibrosis Patients (Visio-Respir)

Cystic Fibrosis

France
Pontificia Universidade Católica do Rio Grande...

Completed

Interactive Video Game Responses in Cystic Fibrosis (Igamecf)

Cystic Fibrosis

Brazil
Children's Hospital of Philadelphia

Completed

Nasal Potential Difference (NPD) for the Diagnosis of Cystic Fibrosis

Cystic Fibrosis

United States
Imperial College London
University of Pennsylvania; University of Oxford; University of Edinburgh; Royal... and other collaborators

Completed

Single Dose of pGM169/GL67A in CF Patients

Cystic Fibrosis

United Kingdom
Vertex Pharmaceuticals Incorporated

Approved for marketing

VX-445/TEZ/IVA Expanded Access Program for Cystic Fibrosis (CF) Patients Heterozygous for F508del Mutation and a Minimal Function Mutation (F/MF Genotypes)

Cystic Fibrosis
Cigdem Emirza
Istanbul University

Completed

Effects of Expiratory Muscle Training on Cough Efficacy in Children and Adolescents With Cystic Fibrosis

Cystic Fibrosis

Turkey
Assistance Publique - Hôpitaux de Paris
Vaincre la Mucoviscidose

Completed

Comparison of Non-invasive Measurement Methods of Hepatic Fibrosis in Cystic Fibrosis (MUCO-FIBRO)

Cystic Fibrosis

France
Augusta University

Completed

Cystic Fibrosis and Endothelial Function: At Rest and During Exercise

Cystic Fibrosis

United States
Hospices Civils de Lyon

Completed

Study of Docosahexanoic Acid in Patients With Cystic Fibrosis (CF) (OMEGAMUCO)

Cystic Fibrosis
Nationwide Children's Hospital
Genentech, Inc.

Completed

Effectiveness of Pulmozyme in Infants With Cystic Fibrosis

Cystic Fibrosis

United States
Galapagos NV

Completed

A Study Looking at the Safety, Tolerability and Efficacy of the Combination of the Study Drugs GLPG2451 and GLPG2222 With or Without GLPG2737 in Patients With Cystic Fibrosis. (FALCON)

Cystic Fibrosis

Belgium, Bulgaria, Germany, Greece, Netherlands, Serbia, Sweden, United Kingdom
Hospices Civils de Lyon

Completed

Gynecological Health Improvement of Adult Women With Cystic Fibrosis (IMPACT)

Cystic Fibrosis
Heart of England NHS Trust
University of Birmingham; National Institute for Health Research, United Kingdom

Completed

A Study of Home Monitoring in Adults With Cystic Fibrosis (HOMECF) (HOME-CF)

Cystic Fibrosis

United Kingdom
University Hospitals Cleveland Medical Center
Cystic Fibrosis Foundation

Completed

Effect of Sulforaphane in Broccoli Sprouts on Nrf2 Activation

Cystic Fibrosis

United States
Papworth Hospital NHS Foundation Trust
University of Sheffield

Suspended

Hyperpolarized Xenon Imaging in Patients With Cystic Fibrosis

Cystic Fibrosis

United Kingdom
Vertex Pharmaceuticals Incorporated

Completed

A Phase 3 Study of Tezacaftor (VX-661) in Combination With Ivacaftor (VX-770) in Subjects Aged 12 Years and Older With Cystic Fibrosis (CF), Who Have One F508del-CFTR Mutation and a Second Mutation That Has Been Demonstrated to be Clinically Responsive to Ivacaftor

Cystic Fibrosis

United States, Australia, Canada, United Kingdom, Germany, Belgium, Austria, Ireland, Italy, France

Clinical Trials on Cystic Fibrosis - Complete

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Sweden

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations